A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.

Registry ID

EUCTR2011-001131-23

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Siena Biotech SpA

Start date

2011-09-21

Completion date

2012-09-18

Last update

2026-08-16

Conditions

• Huntington's disease

Summary

Main objective of the trial is to assess the safety and tolerability of 12 weeks treatment of SEN0014196 at doses of 50 mg and 200 mg once (qd) daily in Huntington’s disease (HD) patients.

Locations

• , , Germany
• , , Italy
• , , UK

View on source registry